Skip to main content

Table 1 Baseline characteristics of study patients

From: Effectiveness and safety assessment of drospirenone/ethinyl estradiol tablet in treatment of PCOS patients: a single center, prospective, observational study

VariablesnEndpointMean ± SD25th50th75thp
Age (years)14024.65 ± 4.3322.0025.0027.75
BMI (kg/m2)140Before22.07 ± 4.0919.0021.3024.75< 0.001
After21.35 ± 3.2218.9221.1823.04
WHR138Before0.86 ± 0.070.820.860.900.026
After0.85 ± 0.060.810.850.89
LOV (cm3)49Before11.80 ± 10.666.739.4512.78< 0.001
After7.46 ± 3.215.136.989.33
ROV (cm3)48Before12.31 ± 10.497.719.3312.020.001
After9.02 ± 6.245.307.7210.62
  1. BMI body mass index; WHR waist-hip ratio; LOV left ovarian volume; ROV right ovarian volume